Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 6Completed 6Active not recruiting 4Unknown 3Terminated 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 20Neoplasm Metastasis 4Neoplasms 3Melanoma 3Thyroid Neoplasms 1Thymus Neoplasms 1Thrombosis 1Thromboembolism 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Inflammation 1Immune System Diseases 1Hormone Receptor Positive Advanced Breast Cancer 1Head and Neck Neoplasms 1HER2+ Breast Cancer 1Gastrointestinal Neoplasms 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1ER Positive, HER2 Negative Breast Cancer 1Colonic Neoplasms 1Chordoma 1Cardiovascular Diseases 1

Interventions

Exercise 18Drug Therapy 17pembrolizumab 12Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Dexamethasone 9Paclitaxel 8Standard of Care 7Oxaliplatin 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Control Groups 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Neoplasms × palbociclib × Clear all
NCT06065592 2023-10-06

CAT_PB

Lebanese University

Phase 1 Unknown
500 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT01522989 2020-03-04

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Georgetown University

Phase 1 Unknown
37 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡